RESUMO
Approximately 10% of global health research is devoted to 90% of global disease burden (the so-called "10/90 Gap") and it often neglects those diseases most prevalent in low-income countries. Antibiotic resistant bacterial infections are known to impact on healthcare, food security, and socio-economic fabric in the developing countries. With a global antibiotic resistance crisis currently reaching a critical level, the unmet needs in the developing countries are even more striking. The failure of traditional antimicrobials has led to renewed interest in century-old bacteriophage (phage) therapy in response to the urgent need to develop alternative therapies to treat infections. Phage therapy may have particular value in developing countries where relevant phages can be sourced and processed locally and efficiently, breaking specifically the economic barrier of access to expensive medicine. Hence this makes phage therapy an attractive and feasible option. In this review, we draw our respective clinical experience as well as phage therapy research and clinical trial, and discuss the ways in which phage therapy might reduce the burden of some of the most important bacterial infections in developing countries.
Assuntos
Antibacterianos/uso terapêutico , Bacteriemia/microbiologia , Endocardite Bacteriana/microbiologia , Terapia por Fagos , Infecções Estafilocócicas/microbiologia , Fagos de Staphylococcus , Staphylococcus aureus/genética , Adulto , Antibacterianos/farmacologia , Bacteriemia/tratamento farmacológico , Bacteriemia/terapia , DNA Bacteriano/análise , DNA Bacteriano/isolamento & purificação , Endocardite Bacteriana/tratamento farmacológico , Endocardite Bacteriana/terapia , Feminino , Humanos , Testes de Sensibilidade Microbiana , Myoviridae , Análise de Sequência de DNA , Infecções Estafilocócicas/terapia , Staphylococcus aureus/efeitos dos fármacos , Staphylococcus aureus/isolamento & purificação , Staphylococcus aureus/virologia , Abuso de Substâncias por Via Intravenosa/complicaçõesRESUMO
We describe a conjugative plasmid appearing in a bacteremic clone of Escherichia coli immediately upon exposure to the antibiotics for which it encoded resistance. Effective antibiotic choice was made possible by prior screening for this plasmid. Surveillance for transmissible resistance plasmids may be clinically important.